Tag: Beyfortus
-
Monoclonal Antibodies Shield Infants from RSV: A New Line of Defense
What is RSV and why is it a concern for infants? Respiratory syncytial virus (RSV) is a common winter illness that typically causes cold-like symptoms. For many healthy adults, it is a mild inconvenience, but for young infants—especially those under six months—or older adults, RSV can lead to serious breathing difficulties and hospital stays. The…
-
Monoclonal Antibodies Shield Infants from RSV
RSV in Infants: A Critical Early Challenge Respiratory syncytial virus (RSV) is a common wintertime pathogen that most healthy adults weather with mild cold-like symptoms. For infants, especially those under six months, RSV can lead to bronchiolitis and pneumonia, sometimes necessitating hospital care. While vaccination strategies for other age groups exist, protecting newborns and very…
-
Monoclonal Antibody Protects Children from RSV: Real-World Evidence
Groundbreaking real-world evidence supports nirsevimab’s role against RSV In a significant step forward for pediatric infectious disease prevention, a large real-world study published in the Journal of Infection provides fresh evidence that the long-acting monoclonal antibody nirsevimab (Beyfortus) offers protection against respiratory syncytial virus (RSV) infection in children. The findings, drawn from diverse clinical settings,…
-
Monoclonal Antibody nirsevimab Beyfortus Shields Children from RSV
New Evidence Supports nirsevimab Beyfortus in RSV Prevention A comprehensive real-world study published in the Journal of Infection highlights the protective role of the long-acting monoclonal antibody nirsevimab, marketed as Beyfortus, against respiratory syncytial virus (RSV) in children. The findings add to the growing body of evidence that this preventive treatment can reduce RSV infections…
-
Monoclonal Antibody Protects Children from RSV: Real-World Insights
RSV’s Burden on Young Lungs Respiratory syncytial virus (RSV) remains a leading cause of hospitalization for infants and young children worldwide. While most kids recover with supportive care, a subset experiences severe disease that can require intensive care. In this context, scientists have been pursuing preventive strategies beyond vaccines, including long-acting monoclonal antibodies that offer…
-
Australia’s RSV immunisation rollout: thousands protected, but gaps remain
New era for infant RSV protection in Australia In 2025, Australia introduced free access to RSV immunisations for all infants, a landmark step in protecting the youngest, most vulnerable Australians from severe respiratory disease. Early indicators are encouraging: sentinel hospital data suggest a substantial drop in RSV-related hospitalisations and intensive care admissions during the peak…
-
Infant RSV immunisation: thousands protected, but gaps remain
Australia’s RSV protection milestone: free infant immunisation for all babies In 2025, Australia rolled out free access to RSV immunisations for all infants, marking a watershed moment in the fight against a virus that routinely causes hospitalisations among young children. Early indicators suggest the program has saved lives and reduced the burden on hospitals, but…
-
Infant RSV Immunisation in Australia: Thousands Protected, Yet Gaps Remain
Introduction: A watershed moment for RSV protection In 2025, Australia introduced free access to RSV immunisations for all infants, supported by the national RSV Mother and Infant Protection Program (RSV-MIPP). Early indicators are promising: thousands of babies have been shielded from severe RSV, and hospital admissions for RSV-related bronchiolitis and pneumonia have fallen compared with…
-
Bronchiolitis Update: Beyfortus Indication Expanded to 24 Months for Vulnerable Kids
What Beyfortus is and how it works Beyfortus, also known as nirsevimab, is a monoclonal antibody designed to protect young children from severe bronchiolitis caused by respiratory syncytial virus (RSV). Unlike vaccines, Beyfortus provides passive immunity through a single intramuscular injection that covers the upcoming RSV season, reducing the risk of hospitalization for RSV-related illness…
-
Bronchiolitis and Beyfortus: Expanded indication for vulnerable children up to 24 months
Overview: Beyfortus and the fight against RSV bronchiolitis Bronchiolitis is a common respiratory illness in young children, most notably caused by the respiratory syncytial virus (RSV). Protecting vulnerable infants and toddlers from severe RSV infections has long been a priority for pediatric care teams. Beyfortus, the synthetic antibody nirsevimab developed by AstraZeneca and marketed by…